reason report
tymlo patch track risk reduc still under-valued pt
bottom line increas price target radiuss stock
base success progress tymlo
pivot trial compani announc final design
statist hurdl initi enrol trial yesterday
believ appropri increas probabl
success program model
increas tymlo franchis revenu estim
new tymlo patch data fda design announc
new data suggest pharmacokinet patch virtual
superimpos exist inject drug fda seem
agre given patch rel wide margin
non-inferior inject pivot trial radiu announc
special protocol assess spa effect guarante
approv patch meet primari statist endpoint pivot
trial power trial design one factor
increas confid drug ultim approv prior
research suggest patch formul could increas market
anabol sever fold word one medacorp
specialist would game changer expect pivot tymlo
patch data approv time unchang
trial big step forward look radiu
match ambit expand clinic develop portfolio
breakthrough formul includ indic
male osteoporosi post fractur heal geographi
includ europ china latin america
opinion radiu stock still substanti undervalu
tymlo franchis reiter outperform rate
increas upsid price target investor like slow
appreci tail valu new product expect
establish near-perpetu compani probabl
biosimilar gener version extrem low patch
tri competitor teriparatid fail cost lead time
develop complex view like challeng
base dcf thru
discount rate termin growth
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
ep exclud stock option expens amort intang
pleas refer page import disclosur price chart analyst certif
price target inc rate stock outperform
radiu biopharmaceut compani uniqu concentr focu drug address
unmet need women health compani revenu today deriv second
subcutan osteoanabol introduc us osteoporosi market tymlo abaloparatid
trajectori tymlo us osteoanabol market share appear predict base
prescript data proprietari medacorp physician survey expect tymlo
obtain share forecast market share provid peak us
sale support valuat radiu stock upsid investor come
potenti introduct tymlo patch pivot test one-year non-inferior
studi sc tymlo data tymlo patch would elimin burden daili
needl inject open much broader prescrib patient base believ
could tripl number patient treat tymlo radiu also develop phase ii asset
call elacestr select estrogen receptor degrad serd late-lin metastat breast
cancer potenti pivot studi underway fast-to-market approach like garner
investor interest valuat support next month price target contain
signific probability-of-success adjust two clinic program
increment valu potenti come tymlo patch program
tymlo patch offer breakthrough patient conveni tymlo patch long
anticip highli valu upgrad current version tymlo abaloparatid
requir daili subcutan sc inject month least accord label
protocol target demograph women year age establish
osteoporosi self-administr sc inject everi day signific treatment burden
psycholog hurdl patient prescrib comparison patch
margin complex exist smoke cessat patch easili use
almost target patient popul almost regardless concomit medic
complaint disabl key question patch whether deliveri
equival drug exposur activ exist inject product secondarili
fda might requir compani approv differ formul
first patient enrol tymlo patch pivot trial data expect pivot
wearabl studi two-arm open-label activ control studi sc tymlo control
studi enrol women us postmenopaus osteoporosi high risk
fractur treat one year either once-daili patch exist tymlo
primari endpoint studi chang lumbar spine bone miner densiti bmd
month studi design non-inferior trial non-inferior margin
absolut differ like increas bone miner densiti sc
version radiu calcul margin preserv histor effect sc tymlo
phase trial placebo-adjust increas lumbar spine bmd
radiu plan finish enrol end would place data
announc earli call radiu disclos power level studi
includ estim dropout rate cover like trial abandon
signific minor sc patient
patch trial initi time expect protocol last year radiu announc align
fda patient non-inferior studi patch sc tymlo
primari endpoint chang lumbar spine bone miner densiti bmd non-
inferior margin suggest sc tymlo lumbar spine bmd increas radiu
guid studi initi compani met timelin surpris
investor materi chang final protocol
special protocol assess spa agreement posit surpris radiu yesterday also
announc receipt special protocol assess spa fda tymlo patch
trial expect spa provid assur trial design properli
conduct suffici regulatori approv product indic question
agreement remov much normal regulatori risk involv single-tri trial develop
plan fraught regulatori pushback protocol design statist
power addit call manag comment fda also align
requir safeti surveil studi
new biomark data continu support tymlo patch radiu previous present
pharmacokinetic/pharmacodynam pk/pd data final patch prototyp consist
match abaloparatid area curv auc exposur sc tymlo strong
correl abaloparatid auc bmd increas previous shown sc
tymlo phase trial radiu yesterday also releas data tymlo patch patient
assess studi patient abl administ daili patch success
rate day wore patch mean minut gave high approv rate
importantli radiu test sensit marker bone format
procollagen type propeptid day studi median level
baselin increas day increas almost exactli
mirror median increas observ sc tymlo phase trial
baselin one month
svb leerink medacorp survey corrobor manag suggest patch
avail tripl osteoanabol market current us patient
treat osteoanabol despit preval osteoporosi patient
fractur radiu intern market research suggest sc rout administr
osteoanabol sever limit patient uptak compani survey result suggest
avail patch could lead tripl number osteoanabol patient
consist proprietari medacorp survey see tymlo start
prescrib survey say share like suggest patch would
doubl current penetr osteoanabol within three year survey specialist
rheumatologist/endocrinologist practic patch avail would also expect
osteoanabol final gain traction primari care provid given improv
administr conveni patch would also increas overal osteoanabol
penetr today ultra-low level
svb leerink tymlo patch po pt current model tymlo patch base
increment osteoanabol market expans market share opportun patch
market versu sc option result tymlo franchis estim
contempl potenti technolog share sc vs patch tymlo franchis base case
sc tymlo includ modest single-digit market increas peak market share
increment patch opportun includ market growth almost tymlo
franchis win market share base patch delta base case
increment case repres tymlo patch estim probabl adjust
base increment pk/pd data fda spa lack surpris phase protocol
increas probabl success tymlo patch result
revenu estim increment tymlo patch opportun increas
peak estim total tymlo franchis remain
increas first year patch increas peak
also decreas sg expens base convers
manag expect year-end cash manag year-end cash
guidanc remain sinc valuat chang result per share
target strike price compani convert debt increas share
outstand valuat share dilut assum convers debt
remov debt balanc valuat convert dilut result price
target reiter outperform rate radiu stock
month price target base dcf methodolog cash flow
termin valu forecast sale subcutan tymlo risk-
adjust sale tymlo patch elacestr assum discount rate base
compani wacc assum convert debt convert stock includ
dilut share calcul price target addit factor
year-end cash balanc valuat
risk view outlook valuat radiu includ major chang price
reimburs coverag unit state sc tymlo compani main product today
forecast product also subject risk better-than-expect market share gain
gener forteo unexpect competit respons forteo manufactur
launch new superior drug class osteoporosi risk radiu includ develop
regulatori disappoint tymlo patch oncolog asset elacestr two
product fail compani valuat would reduc approxim
addit whether tymlo sale match estim on-going clinic trial
success dilut financ like requir product launch order
support futur commerci oper clinic develop
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
complet enrol phase patch
year end
collabor annouc
svb leerink llc research compani file
million
svb leerink research compani file
million
sale
 total revenu
sg total revenu
svb leerink research compani file
mm
pv flow
equiti
debt
